Affordable Access to Weight Loss Drugs: Trump Administration's Agreement with Drugmakers
President Donald Trump announced a new agreement with drugmakers Novo Nordisk and Eli Lilly to reduce the cost of their popular GLP-1 weight loss drugs, Wegovy and Zepbound. The deal will lower the monthly out-of-pocket expenses for these medications, making them more affordable for patients. Currently, the list prices for these drugs are over $1,000 a month, but with the new agreement, patients could pay between $50 and $350 depending on their dosage and insurance coverage.
To increase access to these medications, Costco and Walmart have introduced lower-cost options for patients paying in cash. Costco will sell Wegovy and Ozempic for $499, while Walmart has a similar arrangement for Lilly’s Zepbound. Despite the high list prices, many insurers do not cover these drugs, making it challenging for patients to afford them. The new agreement aims to make these treatments more accessible to millions of patients who have struggled to access them.
The government’s discount platform, TrumpRx, will offer Wegovy and Zepbound at an average monthly cost of $350, which will decrease to $250 within the next two years. Medicare and Medicaid will also cover these drugs, with Medicare patients paying no more than a $50 copay. The drugmakers have agreed to reduce the prices paid by the government for all GLP-1 drugs to $245 a month across all non-starting doses. The administration expects the direct-to-consumer pricing to be available by the end of the year and Medicare coverage by the middle of next year.
This agreement is part of Trump’s initiative to lower prescription drug prices and align them with other developed nations. The deal aims to make these weight loss drugs more affordable for patients, especially those on Medicare and Medicaid. While the details of how the plan will work next year are still unclear, the agreement is a step towards increasing access to these medications for those who need them.